Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
2005 · New England Journal of Medicine · 5,324 citations
https://doi.org/10.1056/nejmoa052122
L
Louis Fehrenbacher
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
216
Papers
58.6K
Citations
78
h-index
138
i10-index
Louis Fehrenbacher is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 78, co-authored 184 publications.
ORCID: 0000-0002-1300-1905Papers by this author
worksMultinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 · Journal of Clinical Oncology · 2,788 citations
https://doi.org/10.1200/jco.1999.17.9.2639
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
2010 · Breast Cancer Research and Treatment · 868 citations
https://doi.org/10.1007/s10549-010-1132-4
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · The Lancet Oncology · 865 citations
https://doi.org/10.1016/s1470-2045(19)30863-0
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
2006 · Breast Cancer Research · 478 citations
https://doi.org/10.1186/bcr1412
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
2012 · New England Journal of Medicine · 466 citations
https://doi.org/10.1056/nejmoa1111097
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat